This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access Fragmin® (dalteparin sodium) prescribing information and adverse event reporting can be found at the bottom of the page.

Risk Factors: VTE in Solid Tumours

The risks of venous thromboembolism (VTE) in cancer1,2

It is estimated that approximately 30% of all first venous thromboembolic events are associated with cancer1.

Cancer patients are up to 7 times more likely to suffer from venous thrombosis compared to patients without neoplasms1,2.

Thromobotic events are the second leading cause of death in cancer patients after death from cancer itself2.

Information on VTE3

  • VTE is a collective term for deep vein thrombosis (DVT) and pulmonary embolism (PE).
  • VTE is a significant cause of mortality, long-term disability and chronic ill-health problems, many of which are avoidable.
  • The incidence of VTE is 1–2 per 1,000 of the population and the risk increases with age.
  • Approximately half of VTE cases are associated with prior hospitalisation for medical illness or surgery.
  • It has been estimated that the management of hospital associated VTE costs the NHS £millions per year.

VTE prevention is an important patient safety issue3

1 in 20 people will have a VTE at some time in their life and approximately half of the cases are associated with prior hospitalisation for medical illness or surgery

VTE causes a larger number of deaths than the combined mortality due to:4

  • Breast cancer
  • HIV
  • Road traffic accidents
VTE is the most common preventable cause of in-hospital death5

General risk factors6*

The general risk factors associated with the development of VTE
​​​​​​​
  • Active cancer or cancer treatment
  • Age >60 years
  • Critical care admission
  • Dehydration
  • Known thrombophilias
  • Obesity (body mass index [BMI] >30 kg/m2)
  • One or more significant medical comorbidities (e.g. heart disease; metabolic, endocrine or respiratory pathologies; acute infectious diseases; inflammatory conditions)
  • Personal history or first-degree relative with a history of VTE
  • Use of hormone replacement therapy (HRT)
  • Use of oestrogen-containing contraceptive therapy
  • Varicose veins with phlebitis

*For women who are pregnant or have given birth within the previous 6 weeks, please see section 1.16 of NICE NG89.

VTE in Solid Tumours

Fragmin Tolerability

Find out more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No